141 related articles for article (PubMed ID: 33391454)
1. Predictive value of tumor mutation burden (TMB) with targeted next-generation sequencing in immunocheckpoint inhibitors for non-small cell lung cancer (NSCLC).
Ma X; Zhang Y; Wang S; Yu J
J Cancer; 2021; 12(2):584-594. PubMed ID: 33391454
[No Abstract] [Full Text] [Related]
2. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
3. The Predictive Value of Tumor Mutation Burden on Efficacy of Immune Checkpoint Inhibitors in Cancers: A Systematic Review and Meta-Analysis.
Wu Y; Xu J; Du C; Wu Y; Xia D; Lv W; Hu J
Front Oncol; 2019; 9():1161. PubMed ID: 31750249
[No Abstract] [Full Text] [Related]
4. Predictive Efficacy of Blood-Based Tumor Mutation Burden Assay for Immune Checkpoint Inhibitors Therapy in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Zhang N; Zhang J; Wang G; He X; Mi Y; Cao Y; Yu X
Front Oncol; 2022; 12():795933. PubMed ID: 35223476
[TBL] [Abstract][Full Text] [Related]
5. Tumor Mutational Burden Predicting the Efficacy of Immune Checkpoint Inhibitors in Colorectal Cancer: A Systematic Review and Meta-Analysis.
Li Y; Ma Y; Wu Z; Zeng F; Song B; Zhang Y; Li J; Lui S; Wu M
Front Immunol; 2021; 12():751407. PubMed ID: 34659255
[TBL] [Abstract][Full Text] [Related]
6. Predictive value of tumor mutational burden for immunotherapy in non-small cell lung cancer: A systematic review and meta-analysis.
Meng G; Liu X; Ma T; Lv D; Sun G
PLoS One; 2022; 17(2):e0263629. PubMed ID: 35113949
[TBL] [Abstract][Full Text] [Related]
7. Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer.
Alborelli I; Leonards K; Rothschild SI; Leuenberger LP; Savic Prince S; Mertz KD; Poechtrager S; Buess M; Zippelius A; Läubli H; Haegele J; Tolnay M; Bubendorf L; Quagliata L; Jermann P
J Pathol; 2020 Jan; 250(1):19-29. PubMed ID: 31471895
[TBL] [Abstract][Full Text] [Related]
8. The Predictive Value of Tumor Mutation Burden on Clinical Efficacy of Immune Checkpoint Inhibitors in Melanoma: A Systematic Review and Meta-Analysis.
Ning B; Liu Y; Wang M; Li Y; Xu T; Wei Y
Front Pharmacol; 2022; 13():748674. PubMed ID: 35355708
[No Abstract] [Full Text] [Related]
9. Immune checkpoint inhibitor (ICI) combination therapy compared to monotherapy in advanced solid cancer: A systematic review.
Ma X; Zhang Y; Wang S; Wei H; Yu J
J Cancer; 2021; 12(5):1318-1333. PubMed ID: 33531977
[No Abstract] [Full Text] [Related]
10. HLA-corrected tumor mutation burden and homologous recombination deficiency for the prediction of response to PD-(L)1 blockade in advanced non-small-cell lung cancer patients.
Shim JH; Kim HS; Cha H; Kim S; Kim TM; Anagnostou V; Choi YL; Jung HA; Sun JM; Ahn JS; Ahn MJ; Park K; Park WY; Lee SH
Ann Oncol; 2020 Jul; 31(7):902-911. PubMed ID: 32320754
[TBL] [Abstract][Full Text] [Related]
11. Comparative effectiveness of combined therapy inhibiting EGFR and VEGF pathways in patients with advanced non-small-cell lung cancer: a meta-analysis of 16 phase II/III randomized trials.
Zhao Y; Wang H; Shi Y; Cai S; Wu T; Yan G; Cheng S; Cui K; Xi Y; Qi X; Zhang J; Ma W
Oncotarget; 2017 Jan; 8(4):7014-7024. PubMed ID: 27690345
[TBL] [Abstract][Full Text] [Related]
12. The predictive value of tumor mutation burden on survival of gastric cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis.
Ke L; Li S; Huang D
Int Immunopharmacol; 2023 Nov; 124(Pt B):110986. PubMed ID: 37748223
[TBL] [Abstract][Full Text] [Related]
13. Tumor Mutational Burden and Efficacy of Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
Kim JY; Kronbichler A; Eisenhut M; Hong SH; van der Vliet HJ; Kang J; Shin JI; Gamerith G
Cancers (Basel); 2019 Nov; 11(11):. PubMed ID: 31731749
[TBL] [Abstract][Full Text] [Related]
14. The predictive value of tumor mutation burden for immune checkpoint inhibitors therapy in non-small cell lung cancer is affected by patients' age.
Wu Y; Xu J; Xu J; Wang Y; Wang L; Lv W; Hu J
Biomark Res; 2020; 8():9. PubMed ID: 32308981
[TBL] [Abstract][Full Text] [Related]
15. The prognostic role of tumor mutation burden on survival of breast cancer: a systematic review and meta-analysis.
Ke L; Li S; Cui H
BMC Cancer; 2022 Nov; 22(1):1185. PubMed ID: 36397030
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of EGFR-TKIs with or without angiogenesis inhibitors in advanced non-small-cell lung cancer: A systematic review and meta-analysis.
Chen Z; Wei J; Ma X; Yu J
J Cancer; 2020; 11(3):686-695. PubMed ID: 31942192
[TBL] [Abstract][Full Text] [Related]
17. Validation of Progression-Free Survival Rate at 6 Months and Objective Response for Estimating Overall Survival in Immune Checkpoint Inhibitor Trials: A Systematic Review and Meta-analysis.
Kok PS; Cho D; Yoon WH; Ritchie G; Marschner I; Lord S; Friedlander M; Simes J; Lee CK
JAMA Netw Open; 2020 Sep; 3(9):e2011809. PubMed ID: 32897371
[TBL] [Abstract][Full Text] [Related]
18. Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer.
Ricciuti B; Kravets S; Dahlberg SE; Umeton R; Albayrak A; Subegdjo SJ; Johnson BE; Nishino M; Sholl LM; Awad MM
J Immunother Cancer; 2019 Mar; 7(1):87. PubMed ID: 30922388
[TBL] [Abstract][Full Text] [Related]
19. VEGFR-TKIs combined with chemotherapy for advanced non-small cell lung cancer: A systematic review.
Liu L; Zhang Y; Wei J; Chen Z; Yu J
J Cancer; 2019; 10(4):799-809. PubMed ID: 30854085
[No Abstract] [Full Text] [Related]
20. The predictive efficacy of tumor mutation burden in immunotherapy across multiple cancer types: A meta-analysis and bioinformatics analysis.
Cao J; Yang X; Chen S; Wang J; Fan X; Fu S; Yang L
Transl Oncol; 2022 Jun; 20():101375. PubMed ID: 35339028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
